Description

GLIPVAS MET TAB is a fixed-dose combination of Vildagliptin 50 mg, a DPP-4 inhibitor, and Metformin Hydrochloride (available in 500 mg, 850 mg, or 1000 mg doses), a biguanide-class antidiabetic. This combination is widely used in the management of type 2 diabetes mellitus (T2DM), especially when single-drug therapy does not provide adequate glycemic control.

• Vildagliptin increases insulin release and decreases glucagon secretion by inhibiting the DPP-4 enzyme, thereby prolonging incretin hormone activity.

• Metformin works by reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity in peripheral tissues.

Together, they offer a complementary mechanism that enhances blood sugar control with a low risk of hypoglycemia and no significant weight gain.

Therapeutic Uses:

• Management of type 2 diabetes mellitus

• Patients uncontrolled on Metformin or Vildagliptin alone

• Combination therapy to reduce fasting and postprandial blood glucose

• Cardiometabolic risk reduction in diabetic patients

Key Benefits:

• Dual-action formula for better glycemic control

• Reduces both fasting and post-meal glucose levels

• Well-tolerated with minimal side effects

• Lower risk of hypoglycemia compared to sulfonylureas

• Once or twice-daily dosing depending on strength

GLIPVAS MET TAB is manufactured in WHO-GMP and ISO-certified facilities and exported globally by BLUEPILL EXPRESS, a trusted name in the international pharmaceutical industry. Available with full regulatory support, export documentation, and private labeling for markets in Asia, Africa, the Middle East, Europe, and Latin America.